Abstract-It has not been clarified whether thresholds of soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PlGF), soluble endoglin, and the sFlt-1/PlGF ratio for the imminent onset of preeclampsia (PE) exist. We hypothesized that onset thresholds for the imminent onset of PE could be determined by the distributions of these 4 markers just after the onset of PE. Study subjects were 51 PE after the onset of PE; 36 of PE, 20 of gestational hypertension, 142 of a small-for-gestational-age infant, and 400 of normal pregnant controls at 19 to 25 and 27 to 31 weeks of gestation in a prospective cohort study. The current data supported our hypothesis that onset thresholds of sFlt-1 and the sFlt-1/PlGF ratio exist. The onset thresholds of the sFlt-1/PlGF at 26 to 31 weeks of gestation were useful for detecting imminent PE with the onset at Ͻ36 weeks of gestation, showing sensitivity of 0.36 and a positive likelihood ratio and 95th percent CIs of 38 (11-132); when positive, PE occurred at 2.2Ϯ0.6 weeks (range: 1.4 -3.0 weeks) after the measurement of the sFlt-1/PlGF ratio. The combination of sFlt-1 at 26 to 31 weeks of gestation, past history of gestational hypertension or PE, prepregnancy body mass index, and mean blood pressure at 16 to 23 weeks of gestation was useful for detecting PE with onset of Ͻ36 weeks of gestation, showing sensitivity of 0.82, and a positive likelihood ratio (95% CI) of 42 (20 -88). In conclusion, the onset threshold of sFlt-1/PlGF existed and might be useful for detecting the imminent onset of PE. (Hypertension. 2011;58:00-00.) • Online Data Supplement Key Words: preeclampsia Ⅲ prediction Ⅲ soluble fms-like tyrosine kinase 1 Ⅲ placental growth factor Ⅲ soluble endoglin Ⅲ prospective cohort study P reeclampsia (PE) is a major complication of pregnancy associated with significant morbidity and mortality of both the fetus and mother. 1,2 Although a detail populationbased database for estimating the incidence rate of PE has not been created in Japan, the incidence rate of PE in unselected pregnant cohorts who sought an antepartum maternal checkup in the first trimester in a tertiary center was 2.5%. 3 Recently, after the discovery of the roles of soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng) in the genesis of preeclamptic rodent model showing hypertension, proteinuria, and glomerular endotheliosis, 4,5 several prospective cohort studies have elucidated that serum/plasma levels of placental growth factor (PlGF), sFlt-1, sEng, and the sFlt-1/PlGF ratio may be useful to predict the occurrence of PE. 6 -12 In preeclamptic women with the clinical manifestation of hypertension and proteinuria, the levels of these 4 markers were more pronounced from the normal reference ranges in women with earlier onset of PE, whereas they were slightly deviated from the normal reference ranges or almost the same levels as normal pregnant women in women with later onset of PE. [13][14][15][16][17][18] [19] [20] [21] [22] This suggested that there are the thresholds for the onset of PE, and the thresholds for the earlier onset of PE are higher than those for the later onset of PE. If the relationship between the onset time of PE and the levels of 4 markers after the onset of PE are represented by some functions of gestational age, we could determine the thresholds for the imminent onset of PE. To clarify this new concept of thresholds determined by the distribution of these 4 markers in women with PE, we designated them as "onset thresholds," whereas we called the conventional thresholds determined by the distribution of these 4 markers in normal pregnant women "abnormal thresholds."
P reeclampsia (PE) is a major complication of pregnancy associated with significant morbidity and mortality of both the fetus and mother. 1, 2 Although a detail populationbased database for estimating the incidence rate of PE has not been created in Japan, the incidence rate of PE in unselected pregnant cohorts who sought an antepartum maternal checkup in the first trimester in a tertiary center was 2.5%. 3 Recently, after the discovery of the roles of soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng) in the genesis of preeclamptic rodent model showing hypertension, proteinuria, and glomerular endotheliosis, 4,5 several prospective cohort studies have elucidated that serum/plasma levels of placental growth factor (PlGF), sFlt-1, sEng, and the sFlt-1/PlGF ratio may be useful to predict the occurrence of PE. 6 -12 In preeclamptic women with the clinical manifestation of hypertension and proteinuria, the levels of these 4 markers were more pronounced from the normal reference ranges in women with earlier onset of PE, whereas they were slightly deviated from the normal reference ranges or almost the same levels as normal pregnant women in women with later onset of PE. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] This suggested that there are the thresholds for the onset of PE, and the thresholds for the earlier onset of PE are higher than those for the later onset of PE. If the relationship between the onset time of PE and the levels of 4 markers after the onset of PE are represented by some functions of gestational age, we could determine the thresholds for the imminent onset of PE. To clarify this new concept of thresholds determined by the distribution of these 4 markers in women with PE, we designated them as "onset thresholds," whereas we called the conventional thresholds determined by the distribution of these 4 markers in normal pregnant women "abnormal thresholds."
If desirable thresholds of the 4 markers of angiogenesisrelated factors for the imminent onset of PE, which are higher at earlier gestational age than at later gestational age, really exist, the thresholds will fulfill the following conditions: (1) the absolute values of correlation coefficients between the onset time of PE and the levels of 4 markers soon after the onset of PE are sufficiently high, Ͼ0.7; (2) Ϯ2.0 SD of regression lines between the onset time of PE and the levels of the 4 markers soon after the onset of PE could be the onset thresholds of the 4 markers, and in almost all PE, the levels of the 4 markers exceed the onset thresholds after the onset of PE; (3) in most women with later onset of PE, the levels of the markers do not exceed the onset thresholds before the onset of PE at earlier gestational age; and (4) in very few normal pregnant women, the levels of the markers exceed the onset thresholds at earlier gestational age. Our first aim was to find such onset thresholds of the 4 markers using samples collected soon after the onset of PE in referred preeclamptic women; the second aim was to evaluate the screening performance of the onset thresholds of the 4 markers and the conventional abnormal thresholds of the 4 markers for predicting all PE, PE with onset at Ͻ36 weeks of gestation, and early onset (EO) PE; the third aim was to evaluate the screening performance of these thresholds for predicting gestational hypertension (GH) or a small-for-gestational-age (SGA) infant; and the fourth aim was to construct a prediction model for PE combining serum levels of angiogenesis-related factors at 19 to 25 or 26 to 31 weeks of gestation and maternal characteristics.
Methods

Subjects and Procedures
The details of subjects and procedures are included in the online Data Supplement (Table 1) . Please see http://hyper.ahajournals.org.
Definitions
We defined GH and PE according to the definition and classification of pregnancy-induced hypertension of the Japan Society for the Study of Hypertension in Pregnancy. 23 In brief, PE was defined as hypertension with proteinuria occurring after the 20th week of gestation but resolving by the 12th week postpartum, whereas GH was defined as hypertension without proteinuria occurring after the 20th week of gestation but resolving by the 12th week postpartum. Hypertension was defined as systolic blood pressure that was Ն140 mm Hg and/or diastolic blood pressure that was Ն90 mm Hg on 2 occasions Ն4 hours apart. Proteinuria was defined as Ն300 mg/d from 24-hour urine collection. If only test tape was available, semiquantitative test results of 1ϩ on 2 occasions Ն1 day apart were considered to constitute a positive result. EO PE was defined as PE with onset at Ͻ32 weeks of gestation, and late-onset PE was defined as PE with onset at Ն32 weeks of gestation. Severe PE was defined as systolic blood pressure Ն160 mm Hg, diastolic blood pressure Ն110 mm Hg, proteinuria Ն2 g/d, or a semiquantitative test 3ϩ. Superimposed PE was defined as chronic hypertension diagnosed before pregnancy or before the 20th week of gestation, with proteinuria emerging after the 20th week of gestation. Superimposed PE was included in the category of PE in this study. We defined an SGA infant as having a birth weight below the 10th percentile for the Japanese population. 24 The multiple of the median for birth weight was calculated as (A Ϫ B)/B (where A is the infant's birth weight and B is the median birth weight at the corresponding gestational week), representing the degree of deviation from the median. All of the diagnoses of PE were decided by K.T., who did not know the ELISA results, reviewing all of the subjects' medical charts.
Establishment of Normal Reference Values of sFlt-1, PlGF, sEng, and sFlt-1/PlGF Ratio
The equations for establishing the normal reference ranges of serum concentrations of sFlt-1, PlGF, sEng, and the sFlt-1/PlGF ratio are included in the online Data Supplement. 15, 17 
Statistics
The detail methods of statistics are included in the online Data Supplement.
Results
In 36 women from whom samples were taken within 1 week after the onset of PE, we analyzed the correlation coefficients between the onset gestational weeks of PE and the logarithmic transformed raw values/SD scores (SDSs) of the 4 markers of angiogenesis-related factors ( Table 2 ). The SDS of log 10 sEng and the SDS of log 10 (sFlt-1/PlGF) showed the highest correlation (Ϫ0.865 and Ϫ0.869, respectively), followed by the SDS of log 10 sFlt-1, the SDS of log 10 PlGF and the raw value of log 10 (sFlt-1/PlGF) (Ϫ0.799, 0.726, and Ϫ0.703, respectively), whereas the absolute values of correlation coefficients of raw values of log 10 sFlt-1, log 10 PlGF, and log 10 sEng were all Ͻ0.7, indicating that the degrees of alteration from the normal reference ranges of the 4 markers, but not raw values, may be closely related to the onset of PE. In Figure 1 , we constructed regression lines between the onset gestational weeks of PE and the SDSs of the 4 markers soon after onset, and their Ϯ2.0 SD, that is, 2.5th and 97.5th percentile confidence lines. We considered the 2.5th percentile lines (thick straight lines in Figure 1A , 1C, and 1D) of log 10 sFlt-1, log 10 sEng, and log 10 (sFlt-1/PlGF) as the onset thresholds of sFlt-1, sEng, and the sFlt-1/PlGF ratio for the imminent onset of PE. All of the SDSs of sFlt-1, sEng, and the sFlt-1/PlGF ratio at sampling in preeclamptic women after the onset of PE were above the onset thresholds ( Figure  1 and Figure 2) . Similarly, we considered the 97.5th percentile line (thick straight line in Figure 1B ) of log 10 PlGF as the onset threshold of PlGF. All of the SDSs of log 10 PlGF at sampling in preeclamptic women after the onset of PE were under the onset threshold.
We evaluated the screening performances of 2 different thresholds of the 4 markers for the later occurrence of PE with onset at Ͻ36 weeks of gestation ( Figure 3, Figure 4 , and Table  3 ). For onset thresholds at 19 to 25 weeks of gestation, PlGF showed moderately high positive likelihood ratio (LRϩ) of 9.5. For abnormal thresholds at 19 to 25 weeks of gestation, PlGF and sFlt-1/PlGF ratio showed moderately high LRϩs of 7.5 and 6.6 with sensitivities of 0.26 and 0.53, respectively. For onset thresholds at 26 to 31 weeks of gestation, the LRϩs for the prediction of PE with onset at Ͻ36 weeks of gestation using onset thresholds of sFlt-1, sEng, and the sFlt-1/PlGF ratio were very high, at 19, 13, and 38 with sensitivities of 0.36, 0.55, and 0.36, respectively. PE occurred at 2.2Ϯ0.6 weeks (range: 1.4 -3.0 weeks) after the measurement of the sFlt-1/PlGF ratio when the levels of the sFlt-1/PlGF ratio were high over the onset threshold at 26 to 31 weeks of gestation, although PE occurred at 7.6Ϯ2.2 weeks (range: 2.1-11.1 weeks) after the measurement of the sFlt-1/PlGF ratio when the levels of the sFlt-1/PlGF ratio were lower under the onset threshold (PϽ0.001). For abnormal thresholds at 26 to 31 weeks of gestation, sFlt-1, sEng, and sFlt-1/PlGF ratio showed moderately high LRϩs of 9.8, 6.2, and 5.3 with sensitivities of 0.73, 0.73, and 0.64, respectively.
We tried to construct combination models using one of the serum levels of angiogenesis-related factors at 19 to 25 or 26 to 31 weeks of gestation and maternal characteristics (Table  3 , S2, S3, S4, and S5). For the prediction of all PE, the combination model using serum levels of sEng at 19 to 25 weeks of gestation, past history of GH/PE, and mean blood pressure (MBP) at 16 to 23 weeks of gestation improved the LRϩ of only using serum levels of sEng from 4.6 to 12.0 without changing the sensitivity of 0.64; and the combination model using serum levels of sFlt-1 at 26 to 31 weeks of gestation, past history of GH/PE, and MBP at 16 to 23 weeks of gestation also improved the LRϩ of only using serum levels of sFlt-1 from 7.1 to 9.5, with improving the sensitivity from 0.48 to 0.76. Likewise, for the prediction of PE with onset of Ͻ36 weeks of gestation, the combination model using serum levels of sEng at 19 to 25 weeks of gestation, previous history of GH/PE, maternal age, and MBP at 16 to 23 weeks of gestation improved the LRϩ of only using serum levels of sEng from 4.8 to 13.0, with improving the sensitivity from 0.74 to 0.84; and the combination model using serum levels of sFlt-1 at 26 to 31 weeks of gestation, past history of GH/PE, prepregnancy body mass index, and MBP at 16 to 23 weeks of gestation markedly improved the LRϩ of only using serum levels of sFlt-1 from 9.8 to 42.0, with improving the sensitivity from 0.73 to 0.82; for the prediction of EO PE, the combination model using serum levels of sFlt-1/PlGF PE indicates preeclampsia; GH, gestational hypertension; SGA, small for gestational age; BMI, body mass index; MBP, mean blood pressure; mRI, mean resistance index; MoM, the multiple of the median.
*Women with an SGA infant were not complicated with either PE or GH. †Normal pregnant women were defined as pregnant women without PE, GH, or an SGA infant. The first 400 normal pregnant women were analyzed. ‡One women with PE, 1 with GH, 4 with SGA, and 1 with normal pregnancy in prospective cohorts lacked data of prepregnancy BMI. §Two women with SGA and 11 with normal pregnancy in a prospective cohorts lacked data of family history of hypertension.
One woman with GH, 10 with SGA, and 15 with normal pregnancy in a prospective cohorts lacked data of current smoking. ¶One woman with PE, 18 with SGA, and 29 with normal pregnancy in prospective cohorts lacked data of bilateral notching at 20 to 23 wk of gestation. #One woman with PE, 17 women with SGA, and 51 with normal pregnancy in prospective cohorts lacked data of mRI at 20 to 23 wk of gestation. **In women with PE, the onset of PE was defined as the gestational weeks when both hypertension and proteinuria occurred. † †Early onset was defined as the onset of PE at Ͻ32 wk of gestation. ‡ ‡Severe PE was defined as systolic blood pressure Ն160 mm Hg, diastolic blood pressure Ն110 mm Hg, or urinary protein excretion Ն2 g/d. § §Small-for-gestational-age infant was defined as Ͻ10th percentile for the Japanese population.
ratio at 19 to 25 weeks of gestation, maternal age, family history of hypertension, and MBP at 16 to 23 weeks of gestation improved the LRϩ of only using serum levels of the sFlt-1/PlGF ratio at 19 to 25 weeks of gestation from 9.3 to 17.0, with improving the sensitivity from 0.78 to 1.00, and the combination model using serum levels of PlGF at 26 to 31 weeks of gestation, MBP at 16 to 23 weeks of gestation, and mean resistance index at 20 to 23 weeks of gestation markedly improved the LRϩ of only using serum levels of PlGF from 4.6 to 122.0, with improving the sensitivity from 0.33 to 1.00. However, we could not construct good combination models for predicting GH or an SGA infant.
Other Results
The comparisons of characteristics and raw/log-transformed data of women with PE after onset of PE, women with PE, GH, and SGA in a prospective cohort study are described in the online Data Supplement (Table 1 and Table S1 ). The equations of onset thresholds and the relations with normal reference values are also written in the online Data Supplement ( Figure 1 and Figure 2 ). The evaluations of onset thresholds and abnormal thresholds for predicting all PE, EO PE, GH, and an SGA infant were written in the online Data Supplement (Table S2 , S3, S4, and S5, Figure 3 , Figure 4 , and Figure S1 ). We also evaluated maternal characteristics for predicting all PE, PE with onset at Ͻ36 weeks of gestation, EO PE, GH, and an SGA infant and wrote the detailed results in the online Data Supplement (Table 3 , S2, S3, S4, and S5).
Discussion
First, we found that onset thresholds of sFlt-1 and sFlt-1/PlGF ratio, but not PlGF and sEng, existed, and the onset threshold of the sFlt-1/PlGF ratio at 26 to 31 weeks of gestation might be useful for detecting imminent PE with onset at Ͻ36 weeks of gestation. Second, we revealed that combination models using one of the serum levels of angiogenesis-related factors at 19 to 25 or 26 to 31 weeks of gestation and maternal characteristics improved the LRϩ and sensitivity for predicting all PE, PE with onset of Ͻ36 weeks of gestation, and EO PE compared with single variable models using only serum levels of angiogenesis-related factors.
In this study, we had hypothesized that desirable onset thresholds of the 4 markers for the imminent onset of PE, which are higher at earlier gestational age than at later gestational age, would fulfill the following 4 conditions: (1) the absolute value of correlation coefficient between the onset time of PE and the levels of 4 markers soon after the onset of PE is sufficiently high, Ͼ0.7; (2) the 2.5th or 97.5th percentile of regression lines between the onset time of PE and the levels of 4 markers soon after the onset of PE could be the onset thresholds of the 4 markers, and in almost all PE, the levels of markers exceed the onset thresholds after the onset of PE; (3) in most women with later onset of PE, the levels of the markers do not exceed the onset thresholds before the onset ratio soon after the onset of PE were the desirable onset thresholds for predicting imminent onset of PE.
The onset threshold levels of sFlt-1 and the sFlt-1/PlGF ratio at earlier gestational age were very high and were extremely deviated from the normal reference ranges of them. In addition, the onset thresholds of sFlt-1 and the sFlt-1/PlGF ratio crossed the abnormal thresholds downward at 31 to 33 weeks of gestation. These findings might explain the following 2 clinically important questions: first, why the incidence rate of earlier onset PE is much lower than the later onset of PE in population-based studies [25] [26] [27] [28] ; and, second, why some cases of late-onset PE lack the increases of sFlt-1 and the sFlt-1/PlGF ratio. Because the levels of sFlt-1 and the sFlt-1/PlGF ratio did not exceed the onset thresholds in women with later occurrence of PE or in normal pregnant women at 19 to 25 weeks of gestation, the extremely high onset threshold levels of sFlt-1 and the sFlt-1/PlGF ratio at earlier gestational age could block the occurrence of PE, if increases in the levels of sFlt-1 and the sFlt-1/PlGF ratio are a necessary condition for the earlier onset of PE. Because the onset thresholds of sFlt-1 and the sFlt-1/PlGF ratio were located under the abnormal thresholds of them after 33 weeks of gestation, PE could occur at later gestational age even if the levels of sFlt-1 and the sFlt-1/PlGF ratio are within the normal reference ranges of them. Actually, 3 in 51 cases of PE occurred within the normal range of sFlt-1 at 36, 38, and 39 weeks of gestation, and 2 in 51 cases of PE occurred within the normal range of the sFlt-1/PlGF ratio at 36 and 38 weeks of gestation ( Figure 2) .
The onset threshold of the sFlt-1/PlGF ratio at 26 to 31 weeks of gestation might be useful for detecting imminent cases of PE with onset at Ͻ36 weeks of gestation. The LRϩ for the prediction of PE with onset at Ͻ36 weeks of gestation was 38 (Table 3) , and PE occurred 2.2 weeks after the measurement on average in 4 cases exceeding the onset threshold of the sFlt-1/ PlGF ratio, whereas PE occurred 7.6 weeks after the measurement on average in 21 cases not exceeding the onset threshold. Thus, the introduction of a new idea of onset threshold may contribute to the detection of imminent PE.
In the current study, we revealed that combination models using one of the serum levels of angiogenesis-related factors at 19 to 25 or 26 to 31 weeks of gestation and maternal characteristics improved the LRϩ and sensitivity for the prediction of all PE, PE with onset of Ͻ36 weeks of gestation, and EO PE compared with those using only serum levels of angiogenesis-related factors. Our results were consistent with the previous reports of a combination model for predicting PE using circulating levels of angiogenesis-related factors and maternal characteristics, including uterine artery flow velocity waveform in the first to second trimester. 12,29 -32 Espinoza et al 29 constructed a combination model for the development of all PE and EO PE using a mean pulsatility index (mPI) and plasma levels of PlGF at 22 to 26 weeks of gestation; the adjusted odds ratio for predicting all PE using mPI was 4.3, that using plasma levels of PlGF of Ͻ280 pg/mL was 2.6, and the combination model using both risk factors yielded the odds ratio of 8.6; the adjusted odds ratio for predicting EO PE using mPI was 24.1, that using plasma levels of PlGF of Ͻ280 pg/mL was 5.5, and the combination using both risk factors yielded the odds ratio of 43.8. Crispi et al 30 constructed the combination model of EO PE and/or fetal growth restriction occurring at Ͻ32 weeks of gestation using uterine artery mPI and serum levels of PlGF in the second trimester; the sensitivity at 95% of specificity increased from 47.4% of using only uterine artery mPI and 84.4% of using only PlGF to 89.5% of the combination model. Poon et al 31 constructed the combination model for predicting EO PE, late-onset PE, and GH using serum levels of PlGF and pregnancy-associated plasma protein-A in the first trimester, maternal characteristics, mean arterial pressure and uterine artery mPI in the first trimester; logistic regression analysis was used to derive algorithms for the prediction of hypertensive disorders. It was estimated that, with the algorithm for early PE, 93.1%, 35.7%, and 18.3% of EO PE, late-onset PE, and GH, respectively, could be detected with a 5% false-positive rate. Thus, the previous reports suggested that the combination of maternal characteristics and circulating levels of PlGF in the first/second trimester is promising for predicting PE, especially EO PE, and our data supported the previous reports. In addition, our data revealed that the combination of maternal characteristics and sEng at 19 to 25 weeks of gestation for predicting all PE and PE with onset of Ͻ36 weeks of gestation and the combination of maternal characteristics and sFlt-1/PlGF ratio at 19 to 25 weeks of gestation for predicting EO-PE showed the more superior predictive accuracy than the combination of maternal characteristics and serum levels of PlGF at 19 to 25 weeks of gestation. Moreover, our current analysis revealed that the combination of maternal characteristics and the serum levels of sFlt-1 at 26 to 31 weeks of gestation markedly improved LRϩ for predicting PE with onset of Ͻ36 weeks of gestation, and the combination of maternal characteristics and the serum levels of PlGF at 26 to 31 weeks of gestation also markedly improved LRϩ for predicting EO-PE, suggesting the combination of maternal characteristics and circulating levels of angiogenesis-related factor in the early third trimester might improve the prediction accuracy for all PE, PE with onset of Ͻ36 weeks of gestation, and EO PE.
Perspectives
Our data support our hypothesis that desirable onset thresholds of sFlt-1 and the sFlt-1/PlGF ratio, which are higher at earlier gestational age than at later gestational age, exist, explaining why the incidence rate of earlier onset PE is much lower than that of the later onset of PE and why some cases of late-onset PE lack increases of sFlt-1 and sEng. In addition, combination models using one of the serum levels of angiogenesis-related factors at 19 to 25 or 26 to 31 weeks of gestation and maternal characteristics improved the LRϩ and sensitivity for predicting all PE, PE with onset of Ͻ36 weeks of gestation, and EO PE. These results indicated that the screening accuracy for predicting PE, especially PE with onset of Ͻ36 weeks of gestation or EO PE, could be improved using onset threshold at 19 to 31 weeks of gestation, which is newly wk indicates weeks of gestation; sFlt-1, soluble fms-like tyrosine kinase 1; PlGF, placental growth factor; sEng, soluble endoglin; LRϩ, positive likelihood ratio; MBP, mean blood pressure; mRI, mean resistance index; NC, not calculated because of very small numbers; GH, gestational hypertension; PE, preeclampsia; BMI, body mass index.
*The appropriate combination model using maternal characteristics of past history of GH/PE, maternal age, family history of hypertension, prepregnancy body mass index (BMI), MBP at 16 to 23 wk, mRI at 20 to 23 wk, and one of the serum levels of angiogenesis-related factors were constructed using multivariate logistic regression analysis with forward stepwise selection procedure. The cutoff value of the model was determined by the receivercharacteristics operating curves, and the sensitivity, specificity, and the LRϩ (95% CI) were calculated using the cutoff value. †The appropriate combination model was constructed by previous history of GH / introduced in the current study, or using a combination model using circulating levels of angiogenesis-related factors at 19 to 31 weeks of gestation and maternal characteristics, such as past history of GH/PE, maternal age, family history of hypertension, prepregnancy body mass index, MBP at 16 to 23 weeks of gestation, and bilateral notching or mean resistance index at 20 to 23 weeks of gestation. However, because our cohorts were relative small, almost all Japanese, and were restricted to only 1 tertiary hospital, the screening accuracy using onset thresholds or combination models should be validated in a larger cohort study in a different population.
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Methods
Subjects and procedures
In 2004, we planned a prospective cohort study to make a prediction model of preeclampsia (PE) using maternal characteristics, such as maternal age, pre-pregnancy body mass index (BMI), nulliparity, choronic hypertension, family history of hypertension, past history of gestational hypertension (GH)/PE, mean blood pressure (MBP), current smoking and bilateral notching (BN) or mean resistance index (mRI), and blood markers such as soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), after approval from the Ethics Committee of our institute. Blood pressure levels were measured at every maternal checkup. Uterine velocity waveforms In this study, the subjects consisted of five groups. The first group was 51 referred preeclamptic women after the onset of PE; the second, third and fourth group were all preeclamptic women (n=36), all women with GH (n=20), and all women with a small-for-gestational-age (SGA) infant (n=142) in a prospective cohort study. The fifth group consisted of the first 400 normal pregnant women without PE, GH or an SGA infant, who were serially recruited early in a prospective cohort study.
In the first group, blood samples were collected once as soon as possible after the onset of PE. The range from the onset to blood sampling was 0.0 -3.2 weeks, and in 36 of the 51 preeclamptic women, the samples were taken within 1 week after the onset of PE. These cases had been previously used to evaluate the deviations of these markers from the reference ranges in women with PE or GH. [1] [2] [3] [4] [5] In the second to fifth groups, the blood samples taken at 19-25 and 26-31 weeks of gestation were used for this study; the sample numbers of PE, GH, an SGA infant and normal controls at 19-25 weeks of gestation were 36, 19, 136 and 384, respectively; and those at 26-31 weeks of gestation were 28, 13, 78 and 312, respectively. In three cases of PE, samples at 26-31 weeks were taken after the onset of PE, therefore, we excluded the samples from the analysis, remaining 25 samples were used.
Serum samples were allowed to clot for almost >6 hrs at 4°C, were centrifuged at 4°C at 2,500 rpm for 15 min, and were stored at −20°C until use. Enzyme-linked immunosorbent assays (ELISAs) for human sFlt-1 (DVR100B, R&D Systems), PlGF (DPG00, R&D Systems) and sEng (DNDG00, R&D Systems) were performed with a single measurement for normal controls and women with an SGA infant, but in duplicate for 82 women who were subjects to identify normal reference ranges of sFlt-1, PlGF, sEng and the sFlt-1/PlGF ratio, 3.5 and in duplicate for women with PE and GH before and after the onset of PE, according to the manufacturer's instructions. The minimal detectable dose in the assays for sFlt-1, PlGF and sEng were 3.5 pg/mL, 7 pg/mL and 7pg/mL, respectively. The intraassay and interassay coefficients of variance for sFlt-1 were 2.6-3.8% and 5.5-9.8%; those for PlGF were 3.6-7.0% and 10.9-11.8%; and those for sEng were 2.8-3.2% and 6.3-6.7%, respectively. 
Blood Pressure in Pregnancy and Puerperal Period
Establishments of normal reference values of sFlt-1, PlGF, sEng and sFlt-1/PlGF ratio
We previously constructed normal reference ranges of serum concentrations of sFlt-1, PlGF, sEng, and the sFlt-1/PlGF ratio. [1] [2] [3] [4] [5] The serial serum data in 82 women in the prospective cohort study were used to establish normal reference values of sFlt-1, PlGF, sEng, and the sFlt-1/PlGF ratio throughout the second half of pregnancy. 3, 5 These data were included into the controls in this study. The data distributions of log 10 sFlt-1, log 10 PlGF, log 10 sEng, log 10 (sFlt-1/PlGF) each week were close to normal distribution using normal P-P plots and Kolmogorov-Smirnov test when the sample size each week was at least 10. 3, 5 The changes from 20 to 38 weeks of gestation of log 10 sFlt-1, log 10 PlGF and log 10 (sFlt-1/PlGF) approximated quadratic curves with constant standard deviations (SDs) through gestational weeks, 5 while that of log 10 sEng approximated quadratic curves with SD represented by a linear function with a positive slope. 3 The following equations show the means, SDs and the 97.5 th percentiles of normal reference curves of log 10 sFlt-1, log 10 (sFlt-1/PlGF), and log 10 sEng, and mean, SD, and the 2.5 th percentile of the normal reference curve of log 10 PlGF. (sFlt-1/PlGF) and log 10 sEng as (A -B) / C (where A is the raw value, B is the mean, and C is the SD). The results are presented as the mean ± SD. For serum sFlt-1, PlGF, the sFlt-1/PlGF ratio and sEng levels, statistical testing was conducted after logarithmic transformation. [1] [2] [3] [4] [5] The unpaired t-test was used to compare two continuous variables, and the analysis of variance followed by multiple comparison was used to compare three or more continuous variables. The chi-square test or Fisher's exact test was used to compare the categorical data. The fitted curve estimation was performed using software included in the SPSS software package (version 13.0J for Windows; SPSS Inc, Chicago, IL). Screening performances, such as sensitivity, specificity, positive likelihood ratio (LR+) and 95% confidence intervals (CIs), for predicting all PE, PE with onset at <36
weeks of gestation, EO-PE, GH and an SGA infant were calculated using all PE, all GH, all SGA infants and 400 normal pregnant women. Significant risk factors by Fisher's exact test were entered into forward stepwise logistic regression to construct combination model using angiogenesis-related factors and maternal characteristics. The LR+ and 95% CIs were calculated using the CONFIDENCE INTERVAL CALCULATOR (created by Rob Herbert in The University of Sydney). 6 LR+ ≥10 was considered useful. P <0.05 was considered significant.
Results
The rates of EO-PE, severe PE, SGA infants, and preterm delivery were higher in women with PE referred after the onset of PE than in those with PE in a prospective cohort study, probably reflecting the selection bias toward serious cases in referred preeclamptic women (Table 1) . Gestational ages at delivery were earlier, infant birth weights were smaller, and the incidence rates of SGA infants were higher in two groups of preeclamptic women than in normal pregnant women. (Table S1 ). The levels of sFlt-1, sEng and sFlt-1/PlGF ratio at 19-25 and 26-31 weeks of gestation were higher in order of an SGA / normal control < GH < PE, and the levels of PlGF at 19-25 and 26-31 weeks of gestation were lower in order of PE / GH / an SGA < normal control.
Since we defined that ± 2.0 standard deviation (SD) of regression lines between the onset time of PE and the levels of the 4 markers soon after the onset of PE are the onset thresholds of the 4 markers, and since we hypothesized that the levels of the 4 markers exceed the onset thresholds after the onset of PE in almost all PE, we considered the 2.5th percentile lines (thick straight lines in Fig. 1A, 1C and 1D ) of log 10 sFlt-1, log 10 sEng and log 10 (sFlt-1/PlGF) as the onset thresholds of sFlt-1, sEng and the sFlt-1/PlGF ratio for the imminent onset of PE, and similarly, we considered the 97.5th percentile line (thick straight line in Fig. 1B Hence, all the onset thresholds were converted from linear functions to quadratic curves (Fig. 2) . The onset threshold of sFlt-1 steeply decreased at earlier gestational age as the gestational age increased, the slope leveled off gradually, approached toward the abnormal threshold of sFlt-1 and finally crossed the abnormal threshold of sFlt-1 at 31
weeks of gestation, then became almost flat after 34 weeks of gestation ( Fig. 2A) . A similar phenomenon was observed for the sFlt-1/PGF ratio; the crossing of the two thresholds occurred at 33 weeks of gestation, then the slope of the onset threshold became almost flat after 36 weeks of gestaion (Fig. 2D) . The onset threshold of sEng showed a different shape from the onset thresholds of sFlt-1 and the sFlt-1/PlGF ratio (Fig. 2C ). It gradually decreased at an earlier gestational age as the gestational age increased, the slope became steeply, approached toward the abnormal threshold of sEng, finally crossed the abnormal threshold of sEng at 33 weeks of gestation, and then remained below the normal reference values of sEng after 38 weeks of gestation, without reaching a nadir like sFlt-1 or the sFlt-1/PlGF ratio. The onset threshold of PlGF showed the mirror image of the onset thresholds of sFlt-1 and the sFlt-1/PlGF ratio, although the crossing of the two thresholds occurred earlier at 25 weeks of gestation (Fig. 2B) . Thus, the onset thresholds of sFlt-1, sEng and the sFlt-1/PlGF ratio more markedly deviated upward from the normal reference ranges at earlier gestation age, while the onset threshold of PlGF slightly deviated downward from the normal reference range at earlier gestational age. In addition, the abnormal thresholds of the 4 markers were within the normal reference range at later gestational age. The tapering of the slopes of the onset thresholds of sFlt-1 and sFlt-1/PlGF at around 38 weeks of gestation suggested that sFlt-1 of >2700 pg/ml and sFlt-1/PlGF ratio of >8 are requisite for the onset of PE.
We evaluated the screening performances of two different thresholds, onset thresholds and abnormal thresholds, of the 4 markers for predicting the later occurrence of all PE (Fig. 3, Fig. 4 , Table S2 ). We evaluate the screening performances of two different thresholds of the 4 markers for the later occurrence of early-onset (EO)-PE (Fig. 3, Fig. 4 , Table S3 ). showed very high LR+ of 12 with sensitivity of 1.00; sEng and sFlt-1/PlGF ratio shwoed moderately high LR+ of 7.9 and 7.9 with sensitivities of 1.00 and 1.00, respectively.
We evaluated the screening performances of two different thresholds of the 4 markers for the later occurrence of GH (Fig. 4, Fig. S1 , Table S4 ). weeks of gestation, suggesting the difficulty of predicting GH using angiogenesis-related factors. We also evaluated the screening performances of two different thresholds of the 4 markers for the later occurrence of an SGA infant without complicating GH or PE (Fig. 4, Fig. S1 , Table S5 ). For onset thresholds at 19-25 and 26-31 weeks of gestation, and for abnormal thresholds at 19-25 and 26-31 weeks of gestation, the LR+s of the 4 markers were all <5, also suggesting the difficulty of predicting an SGA infant using angiogenesis-related factors.
We evaluated the screening performances of maternal characteristics for the later occurrence of all PE, PE with onset of <36 weeks of gestation, EO-PE, GH and an SGA infant ( Table 3, 
Discussion
Abnormal thresholds of angiogenesis-related factors for predicting PE In our current data, abnormal thresholds of PlGF and the sFlt-1/PlGF ratio at 19-25 weeks of gestation were moderately to highly useful for predicting the later occurrence of both PE with the onset at <36 weeks of gestation and EO-PE, whereas abnormal threshold of sFlt-1 at 26-31 weeks of gestation was moderately useful for predicting the later occurrence of all PE. We had previously reported that women with EO-PE showed significantly lower PlGF levels than those with LO-PE at around 20 weeks of gestation before the occurrence of PE in another prospective cohort group. 2 The possibility of predicting PE using angiogenesis-related factors in the second and third trimesters has been reported by other researchers. [7] [8] [9] [10] [11] [12] Levine et al. 7, 8 for the first time reported that the mean level of sFlt-1 in women with PE with onset at <34 weeks at 21-32 weeks of gestation was significantly higher than in controls, and the mean level of PlGF was significantly lower; odds ratios for the prediction of preterm PE at 21-32
weeks of gestation in women with a higher quartile of sEng and the sFlt-1/PlGF ratio were significantly high, suggesting the usefulness of sFlt-1, PlGF, sEng and the sFlt-1/PlGF ratio for predicting PE, especially EO-PE or preterm PE, in the second to early third trimesters in low-risk nulliparous women. Moore Smith et al. 9 reported the area under the ROC curve of the sFlt-1/PlGF ratio at 22-26 weeks of gestation for the prediction of EO-PE was 97% in high-risk women, although the levels of the sFlt-1/PlGF ratio at 22-26 weeks of gestation between women with LO-PE and normal pregnant women were not significantly different. De vivo et al. 10 reported that sEng and the sFlt-1/PlGF ratio at 24-28 weeks of gestation might be useful for predicting both EO-PE and LO-PE; the LR+ of sEng and the sFlt-1/PlGF ratio for predicting all PE were 5.25 and 7.7, respectively. Kusanovic et al. 12 reported that the level of PlGF at 20-25 weeks of gestation has higher LR+ (24) for the prediction of EO-PE with onset at <34 weeks of gestation than the levels of sFlt-1, sEng and sFlt-1/PlGF ratio (LR+: 9.8, 9.8 and 9.2, respectively). In our data, using the cutoff values of the 2.5 th percentile of PlGF and the 97.5 th percentiles of sFlt-1, sEng, and the sFlt-1/PlGF ratio, the LR+ of PlGF and the sFlt-1/PlGF ratio at 19-25 weeks of gestation for predicting PE with onset at <36 weeks of gestation were 7.5 and 6.6, respectively, and those for predicting EO-PE were 12 and 9.3, respectively; the LR+ of sFlt-1, sEng and the sFlt-1/PlGF ratio at 26-31 weeks of gestation for predicting all PE were 7.1, 5.7 and 5.7, respectively.
Taken together our data and others, it is probable that earlier onset of PE could be predicted by PlGF and the sFlt-1/PlGF ratio in the second trimester, and all PE could be predicted by sFlt-1, sEng or the sFlt-1/PlGF ratio early in third trimester. 14 and abnormal uterine artery waveforms in the first and second trimesters 15 are also important risk factors for the development of PE. On the contrary, cigarette smoking during pregnancy is associated with a lower risk of PE. 16 In our data, almost known risk factors were also related to the occurrence of PE in Japanese women, although nulliparity and current smoking was not related to the incidence of PE.
Maternal characteristics related to the occurrence of PE
Reasons of clinical importance for creating prediction models of PE
Prediction of PE, especially early-onset PE or PE with preterm delivery, is very important for the following two reasons. First, the prediction model of PE will facilitate the detection and selection of high risk women for the occurrence of PE, and will increase the referral of such risk women to the hospital with maternal fetal intensive care unit (MFICU). In Japan, almost half of pregnant women have utilized primary obstetrical clinic throughout pregnant period. Therefore, the detection and selection of high risk women is very important to decrease the maternal and fetal motality rate. Until now, Japanese Obstetricians have used the maternal check lists for detecting possible high risk women at the first antepartum maternal checkup, however, it has been very difficult to accurately detect the high risk women with the occurrence of PE in the current check lists. If we will introduce the screening methods for predicting PE using onset thresholds or the combination models, we will be able to detect the high risk women with the later onset of PE more accurately. Second, the construction of accurate prediction model of PE is necessitate for planning the intervention study for preventing the later occurrence of PE using some drugs, such as recombinant PlGF or pravastatin, in a pregnant women. 17, 18 If we can not use such a prediction model with high sensitivity and low false positive rate, and use all primiparous women and multiparous women with past history of GH/PE as the study subjects, the estimated sample size for the randomized controlled trials (RCT) to discriminate a 50% decrease of incidence rate of preterm PE in a Japanese population will be >3000 to secure sufficient statistical power. Therefore, the use of accurate prediction model for PE is necessary to lessen the inclusion numbers of pregnant women in the RCT.
Limitations
In our study, the frequency of sEng >2.5 th percentile of the normal reference range of sEng in 400 normal controls was 9.8% at 19-25 weeks of gestation, and 6.7% at 26-31 weeks of gestation, indicating that the normal reference range of sEng might be wrong; however, we previously pointed out that 3/85 (3.5%) of normal pregnant women showed sustained high sEng levels (>15 ng/ml) during 20-38 weeks of gestation, although these three women showed neither hypertension nor proteinuria during pregnancy. 3 The distribution of sEng in 85 women, including 3 women with high sEng levels, did not show normal distribution, whereas the distribution excluding 3 women with high sEng showed normal distribution; 3 therefore, we created a normal reference range of sEng in only 82 women not showing extremely high levels of sEng >15 ng/ml during 20-38 weeks of gestation. 3 Considering how the reference range of sEng was set, it is possible that 6-10% of women in the current normal controls showed sEng exceeding the 2.5 th percentile of the normal reference range. The normal reference range of sEng might be reset in the future study, using larger normal pregnant controls, and not excluding the extremely high levels of sEng.
In our current data, when the predictions were evaluated by onset thresholds, the sensitivities of onset thresholds were low in cases of sFlt-1 and sFlt-1/PlGF in spite of high likelihood ratio of those markers. We speculate that this low sensitivity of onset thresholds using sFlt-1 and sFlt-1/PlGF might occur due to small sampling times (only 1-2 times) before the onset of PE. All values of sFlt-1 and sFlt-1/PlGF in women with PE referred after onset were over than the onset thresholds. If we had taken samples more frequently (for example, every 2-4 weeks), sensitivities of the onset thresholds of sFlt-1 and sFlt-1/PlGF for predicting all PE, PE with onset at <36 weeks of gestation and early-onset PE might have increased. Another possible explanation of low sensitivities of onset thresholds may be the facts that all 3 cases in whom PE had already occurred at 26-31 weeks of gestation before taking samples showed the levels of sFlt-1 and sFlt-1/PlGF ratio over than the onset thresholds (data not shown). Therefore, we speculate that PE may occur in some pregnant women immediately after the levels of sFlt-1 and sFlt-1/PlGF ratio becoming over than the thresholds. Table S1 Serum levels of sFlt-1, PlGF, sFlt-1/PlGF ratio and sEng in women with PE referred after onset, and in women with PE, GH, an SGA infant, and normal pregnancy in a prospective cohort study. 
Figure S1
The figures represent the location of the raw values of sFlt-1, PlGF, sEng and the sFlt-1/PlGF ratio at 19-31 weeks of gestation in 20 women with gestational hypertension (GH) (large closed circles) and 142 women complicated with a small-for-gestational-age (SGA) infant (small open diamonds) against the onset thresholds. We drew onset thresholds (thick straight curves) on scattergrams representing the relationship between the gestational weeks at sampling and the raw values of log 10 sFlt-1(A), log 10 PlGF (B), log 10 sEng (C) and log 10 (sFlt-1/PlGF) (D). Dashed and dotted curves represent the 2.5 th and 97.5 th percentiles of normal reference ranges of the 4 markers, and dotted lines represent the means of normal reference ranges of the 4 markers. Thick dashed and dotted curves represent abnormal thresholds. Abbreviations: sFlt-1, soluble fms-like tyrosine kinase 1; PlGF, placental growth factor; sEng, soluble endoglin.
